Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Common Equity (2016 - 2025)

Surgery Partners' Common Equity history spans 12 years, with the latest figure at $1.7 billion for Q4 2025.

  • For Q4 2025, Common Equity fell 4.29% year-over-year to $1.7 billion; the TTM value through Dec 2025 reached $1.7 billion, down 4.29%, while the annual FY2025 figure was $1.7 billion, 4.29% down from the prior year.
  • Common Equity for Q4 2025 was $1.7 billion at Surgery Partners, down from $3.1 billion in the prior quarter.
  • Across five years, Common Equity topped out at $3.2 billion in Q2 2024 and bottomed at $1.1 billion in Q1 2021.
  • The 5-year median for Common Equity is $2.9 billion (2022), against an average of $2.5 billion.
  • The largest annual shift saw Common Equity soared 123.29% in 2021 before it tumbled 41.02% in 2024.
  • A 5-year view of Common Equity shows it stood at $2.0 billion in 2021, then skyrocketed by 49.31% to $2.9 billion in 2022, then rose by 3.18% to $3.0 billion in 2023, then crashed by 41.02% to $1.8 billion in 2024, then dropped by 4.29% to $1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for SGRY's Common Equity are $1.7 billion (Q4 2025), $3.1 billion (Q3 2025), and $3.2 billion (Q2 2025).